The intravenous therapy solutions market size has grown rapidly in recent years. It will grow from $13.17 billion in 2025 to $14.53 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to growing hospital infrastructure, rising incidence of dehydration and electrolyte imbalance, increasing adoption of iv therapy in clinics, technological advancements in iv solutions, rising surgical procedures.
The intravenous therapy solutions market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing home healthcare adoption, rising demand for personalized nutrition and medication administration, technological integration with digital health platforms, expansion in emerging markets, growth in chronic disease management. Major trends in the forecast period include personalized iv therapy solutions, portable and home-based iv devices, infection control and safety enhancements, advanced electrolyte and nutrient formulations, integration with electronic health records (ehr).
The increasing demand for minimally invasive therapies is expected to drive growth in the intravenous therapy solutions market. Minimally invasive therapies involve medical treatments with minimal incisions or bodily entry, often resulting in quicker recovery and fewer complications. This rising preference is attributed to the therapies’ ability to reduce postoperative pain, leading to faster recovery and greater patient comfort during healing. Intravenous therapy solutions facilitate these treatments by delivering fluids, medications, and nutrients directly into the bloodstream, promoting effective patient care and accelerated recovery. For example, in June 2024, the American Society of Plastic Surgeons reported that minimally invasive procedures increased by 7% in 2023, surpassing the growth rate of surgical procedures by 2%. Hence, the rising demand for minimally invasive therapies is fueling the expansion of the intravenous therapy solutions market.
Key players in the intravenous therapy solutions market are focusing on innovative products such as ready-to-use drug infusions to improve treatment efficiency and reduce preparation time in clinical environments. Ready-to-use drug infusions consist of pre-mixed and pre-labeled intravenous medications packaged in standardized doses, eliminating the need for on-site dilution or compounding. In May 2024, B. Braun Medical Inc., a US-based manufacturer, introduced Levetiracetam in Sodium Chloride Injection, a ready-to-use intravenous anticonvulsant solution designed for seizure treatment. This product comes in standardized concentrations and volumes, removing the requirement for dilution or compounding at the point of care. The formulation is pre-mixed in a flexible container to ensure dosing accuracy, reduce contamination risks, and improve convenience for healthcare providers in emergency and inpatient settings.
In April 2025, Organon & Co., a US-based healthcare company, acquired the regulatory and commercial rights to Tofidence from Biogen Inc. This acquisition aims to strengthen and expand Organon & Co.’s biosimilars immunology portfolio in the US by including Tofidence to support treatments for multiple arthritis conditions and COVID-19. The company plans to leverage its commercial expertise and market access capabilities to foster long-term growth in the immunology sector. Biogen Inc. is a US-based biotechnology firm specializing in intravenous therapy solutions like Tofidence.
Major companies operating in the intravenous therapy solutions market are Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Terumo Corporation, Dr. Reddy’s Laboratories Limited, Sichuan Kelun Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Biocon Limited, B. Braun Melsungen Aktiengesellschaft, JW Life Science Corporation, AdvaCare Pharma USA, Soxa Formulations & Research Pvt. Ltd., Vifor Pharma Management Ltd., Aetos Pharma Private Limited, LXIR Medilabs Private Limited, Amanta Healthcare Limited, Aculife Healthcare Private Limited, Claris Lifesciences Limited, Osel Lifesciences Pvt. Ltd., BBraun Avitum AG.
North America was the largest region in the intravenous therapy solutions market in 2025. The regions covered in the intravenous therapy solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous therapy solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the intravenous therapy solutions market by increasing the cost of imported raw materials such as saline, glucose, and specialty nutrients, leading to higher production costs for manufacturers. The segments most affected include crystalloids and colloids, particularly in regions like North America and Europe, which rely on imports from Asia-Pacific. While tariffs have posed challenges in supply chain efficiency, they have also encouraged local manufacturing and innovation, creating opportunities for domestic production of cost-effective intravenous solutions.
The intravenous therapy solutions market research report is one of a series of new reports that provides intravenous therapy solutions market statistics, including intravenous therapy solutions industry global market size, regional shares, competitors with a intravenous therapy solutions market share, detailed intravenous therapy solutions market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous therapy solutions industry. This intravenous therapy solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Intravenous therapy solutions are sterile liquid formulations administered directly into the bloodstream to deliver fluids, medications, nutrients, or electrolytes. These solutions are used to treat conditions such as dehydration, electrolyte imbalances, infections, and to provide essential nutrients when oral intake is not feasible. Typically composed of water, salts, sugars, or medicinal ingredients, they are customized based on individual patient requirements and specific medical conditions.
The primary types of intravenous therapy solutions include crystalloids, colloids, blood products, and others. Crystalloids consist of water mixed with electrolytes and are commonly used for rapid rehydration and fluid balance restoration in urgent medical situations. These solutions serve multiple purposes, including correcting fluid and electrolyte imbalances, supporting nutrition, administering medications, and enabling blood transfusions. They are utilized across a range of healthcare settings, including hospitals, clinics, ambulatory surgical centers, home care environments, and more.
The intravenous therapy solutions market consists of sales of saline solutions, dextrose solutions, lactated Ringer’s solutions, amino acid solutions, vitamin and mineral infusions, IV antibiotic solutions, chemotherapy IV solutions, and parenteral nutrition solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The intravenous therapy solutions market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to increasing home healthcare adoption, rising demand for personalized nutrition and medication administration, technological integration with digital health platforms, expansion in emerging markets, growth in chronic disease management. Major trends in the forecast period include personalized iv therapy solutions, portable and home-based iv devices, infection control and safety enhancements, advanced electrolyte and nutrient formulations, integration with electronic health records (ehr).
The increasing demand for minimally invasive therapies is expected to drive growth in the intravenous therapy solutions market. Minimally invasive therapies involve medical treatments with minimal incisions or bodily entry, often resulting in quicker recovery and fewer complications. This rising preference is attributed to the therapies’ ability to reduce postoperative pain, leading to faster recovery and greater patient comfort during healing. Intravenous therapy solutions facilitate these treatments by delivering fluids, medications, and nutrients directly into the bloodstream, promoting effective patient care and accelerated recovery. For example, in June 2024, the American Society of Plastic Surgeons reported that minimally invasive procedures increased by 7% in 2023, surpassing the growth rate of surgical procedures by 2%. Hence, the rising demand for minimally invasive therapies is fueling the expansion of the intravenous therapy solutions market.
Key players in the intravenous therapy solutions market are focusing on innovative products such as ready-to-use drug infusions to improve treatment efficiency and reduce preparation time in clinical environments. Ready-to-use drug infusions consist of pre-mixed and pre-labeled intravenous medications packaged in standardized doses, eliminating the need for on-site dilution or compounding. In May 2024, B. Braun Medical Inc., a US-based manufacturer, introduced Levetiracetam in Sodium Chloride Injection, a ready-to-use intravenous anticonvulsant solution designed for seizure treatment. This product comes in standardized concentrations and volumes, removing the requirement for dilution or compounding at the point of care. The formulation is pre-mixed in a flexible container to ensure dosing accuracy, reduce contamination risks, and improve convenience for healthcare providers in emergency and inpatient settings.
In April 2025, Organon & Co., a US-based healthcare company, acquired the regulatory and commercial rights to Tofidence from Biogen Inc. This acquisition aims to strengthen and expand Organon & Co.’s biosimilars immunology portfolio in the US by including Tofidence to support treatments for multiple arthritis conditions and COVID-19. The company plans to leverage its commercial expertise and market access capabilities to foster long-term growth in the immunology sector. Biogen Inc. is a US-based biotechnology firm specializing in intravenous therapy solutions like Tofidence.
Major companies operating in the intravenous therapy solutions market are Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Baxter International Inc., Fresenius Kabi AG, Grifols S.A., Terumo Corporation, Dr. Reddy’s Laboratories Limited, Sichuan Kelun Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Biocon Limited, B. Braun Melsungen Aktiengesellschaft, JW Life Science Corporation, AdvaCare Pharma USA, Soxa Formulations & Research Pvt. Ltd., Vifor Pharma Management Ltd., Aetos Pharma Private Limited, LXIR Medilabs Private Limited, Amanta Healthcare Limited, Aculife Healthcare Private Limited, Claris Lifesciences Limited, Osel Lifesciences Pvt. Ltd., BBraun Avitum AG.
North America was the largest region in the intravenous therapy solutions market in 2025. The regions covered in the intravenous therapy solutions market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the intravenous therapy solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the intravenous therapy solutions market by increasing the cost of imported raw materials such as saline, glucose, and specialty nutrients, leading to higher production costs for manufacturers. The segments most affected include crystalloids and colloids, particularly in regions like North America and Europe, which rely on imports from Asia-Pacific. While tariffs have posed challenges in supply chain efficiency, they have also encouraged local manufacturing and innovation, creating opportunities for domestic production of cost-effective intravenous solutions.
The intravenous therapy solutions market research report is one of a series of new reports that provides intravenous therapy solutions market statistics, including intravenous therapy solutions industry global market size, regional shares, competitors with a intravenous therapy solutions market share, detailed intravenous therapy solutions market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous therapy solutions industry. This intravenous therapy solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Intravenous therapy solutions are sterile liquid formulations administered directly into the bloodstream to deliver fluids, medications, nutrients, or electrolytes. These solutions are used to treat conditions such as dehydration, electrolyte imbalances, infections, and to provide essential nutrients when oral intake is not feasible. Typically composed of water, salts, sugars, or medicinal ingredients, they are customized based on individual patient requirements and specific medical conditions.
The primary types of intravenous therapy solutions include crystalloids, colloids, blood products, and others. Crystalloids consist of water mixed with electrolytes and are commonly used for rapid rehydration and fluid balance restoration in urgent medical situations. These solutions serve multiple purposes, including correcting fluid and electrolyte imbalances, supporting nutrition, administering medications, and enabling blood transfusions. They are utilized across a range of healthcare settings, including hospitals, clinics, ambulatory surgical centers, home care environments, and more.
The intravenous therapy solutions market consists of sales of saline solutions, dextrose solutions, lactated Ringer’s solutions, amino acid solutions, vitamin and mineral infusions, IV antibiotic solutions, chemotherapy IV solutions, and parenteral nutrition solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Intravenous Therapy Solutions Market Characteristics
3. Intravenous Therapy Solutions Market Supply Chain Analysis
4. Global Intravenous Therapy Solutions Market Trends and Strategies
5. Intravenous Therapy Solutions Market Analysis of End Use Industries
7. Global Intravenous Therapy Solutions Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Intravenous Therapy Solutions Total Addressable Market (TAM) Analysis for the Market
9. Intravenous Therapy Solutions Market Segmentation
10. Intravenous Therapy Solutions Market Regional and Country Analysis
11. Asia-Pacific Intravenous Therapy Solutions Market
12. China Intravenous Therapy Solutions Market
13. India Intravenous Therapy Solutions Market
14. Japan Intravenous Therapy Solutions Market
15. Australia Intravenous Therapy Solutions Market
16. Indonesia Intravenous Therapy Solutions Market
17. South Korea Intravenous Therapy Solutions Market
18. Taiwan Intravenous Therapy Solutions Market
19. South East Asia Intravenous Therapy Solutions Market
20. Western Europe Intravenous Therapy Solutions Market
21. UK Intravenous Therapy Solutions Market
22. Germany Intravenous Therapy Solutions Market
23. France Intravenous Therapy Solutions Market
24. Italy Intravenous Therapy Solutions Market
25. Spain Intravenous Therapy Solutions Market
26. Eastern Europe Intravenous Therapy Solutions Market
27. Russia Intravenous Therapy Solutions Market
28. North America Intravenous Therapy Solutions Market
29. USA Intravenous Therapy Solutions Market
30. Canada Intravenous Therapy Solutions Market
31. South America Intravenous Therapy Solutions Market
32. Brazil Intravenous Therapy Solutions Market
33. Middle East Intravenous Therapy Solutions Market
34. Africa Intravenous Therapy Solutions Market
36. Intravenous Therapy Solutions Market Competitive Landscape and Company Profiles
37. Intravenous Therapy Solutions Market Other Major and Innovative Companies
40. Intravenous Therapy Solutions Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Intravenous Therapy Solutions Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses intravenous therapy solutions market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for intravenous therapy solutions? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The intravenous therapy solutions market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Crystalloids; Colloids; Blood Products; Other Product Types2) By Application: Fluid And Electrolyte Imbalance; Nutritional Support; Medication Administration; Blood Transfusion; Other Applications
3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Home Care Settings; Other End-Users
Subsegments:
1) By Crystalloids: Normal Saline (0.9% Sodium Chloride); Half Normal Saline (0.45% Sodium Chloride); Lactated Ringer’s Solution; Dextrose Solutions; Hypertonic Saline2) By Colloids: Albumin; Dextran; Hydroxyethyl Starch (HES); Gelatin
3) By Blood Products: Packed Red Blood Cells (PRBCs); Platelets; Fresh Frozen Plasma (FFP); Cryoprecipitate
4) By Other Product Types: Intravenous Immunoglobulins (IVIG); Parenteral Nutrition Solutions; Specialty Intravenous Drugs And Additives
Companies Mentioned: Pfizer Inc.; Otsuka Pharmaceutical Co. Ltd.; Baxter International Inc.; Fresenius Kabi AG; Grifols S.A.; Terumo Corporation; Dr. Reddy’s Laboratories Limited; Sichuan Kelun Pharmaceutical Co. Ltd.; Hikma Pharmaceuticals PLC; Biocon Limited; B. Braun Melsungen Aktiengesellschaft; JW Life Science Corporation; AdvaCare Pharma USA; Soxa Formulations & Research Pvt. Ltd.; Vifor Pharma Management Ltd.; Aetos Pharma Private Limited; LXIR Medilabs Private Limited; Amanta Healthcare Limited; Aculife Healthcare Private Limited; Claris Lifesciences Limited; Osel Lifesciences Pvt. Ltd.; BBraun Avitum AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Intravenous Therapy Solutions market report include:- Pfizer Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Baxter International Inc.
- Fresenius Kabi AG
- Grifols S.A.
- Terumo Corporation
- Dr. Reddy’s Laboratories Limited
- Sichuan Kelun Pharmaceutical Co. Ltd.
- Hikma Pharmaceuticals PLC
- Biocon Limited
- B. Braun Melsungen Aktiengesellschaft
- JW Life Science Corporation
- AdvaCare Pharma USA
- Soxa Formulations & Research Pvt. Ltd.
- Vifor Pharma Management Ltd.
- Aetos Pharma Private Limited
- LXIR Medilabs Private Limited
- Amanta Healthcare Limited
- Aculife Healthcare Private Limited
- Claris Lifesciences Limited
- Osel Lifesciences Pvt. Ltd.
- BBraun Avitum AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 14.53 Billion |
| Forecasted Market Value ( USD | $ 21.25 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
